Drug Profile

Ceftolozane/tazobactam - Merck Sharp & Dohme

Alternative Names: CXA-101/tazobactam; CXA-101/YTR-830H; CXA-201; MK-7625A; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa

Latest Information Update: 19 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astellas Pharma
Developer M. D. Anderson Cancer Center; Merck Sharp & Dohme
Class 2 ring heterocyclic compounds; Anti-infectives; Anti-inflammatories; Antibacterials; Cephalosporins; Small molecules; Sulfones; Triazoles; Urinary anti-infective agents
Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
Registered Pyelonephritis
Phase II Bacterial infections

16 Mar 2025 Weill Medical College of Cornell University in collaboration with Merck Sharp & Dohme terminates a phase I/II trial for Bacterial infections in USA (IV) (NCT04673175)
14 Sep 2024 Ceftolozane/tazobactam is still in phase I MK-7625A-036 clinical trials in Ventilator-associated-pneumonia (In adolescents, In children, In infants, In neonates) in Spain, Estonia, Greece, Russia, Ukraine and the US (IV) (NCT04223752) (EudraCT2018-004704-19) (EudraCT2022-501110-56-00)
14 Sep 2024 Merck Sharp & Dohme LLC completes phase I MK-7625A-036 clinical trials in Ventilator-associated-pneumonia (In adolescents, In children, In infants, In neonates) in Mexico, Chile, Colombia, Spain, Estonia, Greece, Russia, Ukraine and the US (IV) (NCT04223752) (EudraCT2018-004704-19) (EudraCT2022-501110-56-00)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com